Science Explorer Back to mapMap

Most cited papers from MyeloRx (United States)

What are the most cited papers from MyeloRx (United States)?

The most cited paper from MyeloRx (United States) is "MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML" (B Z Carter, Duncan H. F. Mak, Yue Xi Shi et al., 2011), with 43 citations. Next come "The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer" (37) and "Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102" (20).

Showing 6 of 6 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML B Z Carter, Duncan H. F. Mak, Yue Xi Shi et al. · Leukemia Open access 9 Sep 2011 43
2 The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer Theresa A. Reno, Sun-Wing Tong, Jun Wu et al. · BMC Cancer Open access 11 Jul 2016 37
3 Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102 John M. Fidler, Jinhua An, Bing Z. Carter et al. · Cancer Chemotherapy and Pharmacology Open access 11 Mar 2014 20
4 Preclinical Development of Triptolide Derivative MRx102 as a Therapeutic Agent for Acute Myeloid Leukemia John M. Fidler, Jinhua An, JOHN H. MUSSER et al. · Blood 19 Nov 2010 1
5 MRx102, a Novel Triptolide Analogue, Has Low Nanomolar Activity Against AML Stem/Progenitor Cells in Vitro and in a Murine Model of AML Bing Z. Carter, Duncan H. F. Mak, Yuxie Shi et al. · Blood 18 Nov 2011 0
6 The Antitumor Effects of MRx102: Novel, Potent, and Synergistic Zhenhuan Zhang, Menglun Zhang, Shih‐Hsien Yang et al. · International Journal of Radiation Oncology*Biology*Physics 25 Oct 2012 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.